



Organisation  
of European  
Cancer Institutes



In collaboration with

 Fondazione IRCCS  
Istituto Nazionale dei Tumori

· Sistema Socio Sanitario

 Regione  
Lombardia

# Oncology Days

 OECD43

**PROMOTING INNOVATION  
AND QUALITY FOR PATIENTS**

**MILAN 2021**  
**SCIENTIFIC CONFERENCES**

*June 16<sup>th</sup> 2021*

**VIRTUAL  
EVENT** 



SECOND  
ANNOUNCEMENT

*Oncology Days 2022*

June, 2022 - Valencia, Spain



# OECI2021 ONCOLOGY DAYS

## Welcome to OECI 43

Dear OECI Members,

It is our pleasure to introduce you all to the virtual edition of the OECI Oncology Day 2021.

Unfortunately, once again, due to the difficulties arisen by the COVID-19, we had to postpone our meeting in presence and organise a virtual event. We hope, however, to greet you all in person next year over in Valencia, where the OECI Oncology Days 2022 will take place, thanks to the kind support of the Fundacion Instituto Valenciano de Oncologia.

Before introducing the scientific sessions, we would like to first spend a few words and take a look together at the current European cancer landscape and its latest developments and initiatives.

Cancer is part of the humans's history and unfortunately, it is very much part of our present too – all our families have been touched in some way by the disease. Every year almost 4 million European citizens are diagnosed with cancer, which is Europe's second leading cause of death – it claimed more than 1.3 million lives last year. That is a shocking figure and this number is expected to continue to rise. The COVID pandemic is expected to contribute to worsening the figures as well.

It is only by working together, by listening to one another, and by taking practical actions, in synergy with each other, that we can effectively respond to the complex and multifaceted demands of cancer treatment, care, and research. At the same time, the requests of the healed patients must also be taken into account. It is mandatory to support them by soothing their fears, offering the best rehabilitation procedures and helping them to easily reintegrate in the social and family journey.

As the EU Commissioner for Health and Food Safety said, and I quote:

*"No country alone has the knowledge and capacity to treat all rare and complex conditions."*

We must therefore continue cooperating, to share life-saving knowledge at a European level, and beyond.

The European Union has recognised this societal challenge and has already made great stride: the Framework Programme Horizon Europe is, in fact, putting on the table a mission-oriented approach with a Mission Board which is working with an Assembly, in order to make conquering cancer within the next 7 years a "mission possible". As you all know, the Cancer Mission Board suggested **13 Recommendations** whose ultimate goal is to transfer the best possible cancer culture **all across Europe**.

In **low-resourced countries**, in fact, there are still numerous barriers to take down. These include, for instance, poor access to health services and inadequate diagnostic facilities. Within the European Union, there are particularly worrying indicators suggesting that **survival rate inequalities are a major challenge, with worse outcomes experienced in Eastern European countries**.

So how do we transform this worrying scenario into a productive area of dynamic change? How do we pave the way to handling economic and social inequalities in countries with less developed systems?

The Mission Cancer Board answers this question by suggesting to combine innovative

*Oncology Days 2023*

June, 2023 - Paris, France



*Oncology Days 2024*

June, 2024 - Helsinki, Finland



*Oncology Days 2025*

June, 2025 - Oslo, Norway





prevention and treatment strategies in a **sustainable state-of-the-art virtual European cancer centre/infrastructure**. This way it will be possible to **achieve a long-term survival of 3 out of 4 cancer patients in countries with well-developed healthcare systems by 2030**. This is the ambitious challenge put forward by the European Cancer Mission.

The Mission Board and Assembly suggestions will be used as a basis for further stakeholder and citizen engagement activities during the rest of 2021. Synergies will be developed with other European Union policies and actions, in particular **Europe's Beating Cancer Plan**, which was presented by the EU Commissioner Stella Kyriakides on February 3<sup>rd</sup> 2021.

**The aim of Europe's Beating Cancer Plan is to tackle the entire disease pathway**, with four main action areas: (1) prevention; (2) early detection; (3) diagnosis and treatment; and (4) quality of life of cancer patients and survivors. In order to achieve this the EU will provide substantial financial support with €4 billion to Member States in their efforts to make their health systems more robust.

As we said before, cancer must be fought on several fronts and in order for us to realize the potential of these instruments put forward by the European Union. Health professionals, researchers, as well as entrepreneurs and non-profits must collaborate in implementing these initiatives bottom-up. We must harness these new opportunities and make sure that protecting our patients, collaborating and proactively listening to them is built into our efforts from day one.

This is a very exciting time for the entire cancer community and the OECl, the biggest worldwide cancer network. We must not forget that it is patients who have the most at stake in these efforts and we must **work with them, not only for them**. Patients cannot be on the sidelines.

The OECl intends to be an active actor of the incoming European initiatives, where I hope our massive network of Members may find a role for their running activities with some of the 13 Recommendations set out.

Let us take also the opportunity to mention the developments which marked the OECl activities and initiatives over the past year, which has been considerably burdened by the restrictions imposed by the COVID-19 pandemic.

One of the main challenges that has produced a fertile ground of debate within the OECl over the past year was the **question of multidisciplinary in care**. As a matter of fact, the increasing complexity of cancer care raises the question of **the role assigned to multidisciplinary care, as opposed to the organ-based approach**, for health systems in general and for quality of care, in particular in the organisation of cancer services. The literature on the subject clearly associates a pan-cancer approach to cancer care with better adherence to clinical practice guidelines and enhanced co-ordination of hospital services.

What's more, whilst several national health system across the EU recognise multidisciplinary care as a health priority, OECl is currently the only European Cancer Organisation whose quality Programme, certified by ISQua, the International Society for Quality in Health Care, is based on a multidisciplinary approach.

OECl certified centres span all across Europe, and we are approaching the remaining ones to attract their cancer infrastructures to the OECl membership and thus endorse quality improvement in those countries where advancement is still needed. OECl is aware that the

standards that may be certified in some of the most prominent cancer centres cannot be imposed "toutcourt" to minor centres or cancer departments located in Region/Countries with a very low PPP. This is why the Accreditation and Designation Programme is working to create the conditions to overcome this critical point.

We would hereby like to extend our gratitude to the Chairs of the Oncology Day 2021 to whom is entrusted the task to explain how OECl is approaching major cancer core objectives to increase quality, reduce the burden of the too high cost of drugs, apply the best available protocols and design the future of care with patients.

As already mentioned, we want to grow together in order to reduce present-day inequalities and offer all European citizens the same quality of care. This is the reason why OECl decided to set-up a Working Group on "Collaboration for Good Practices with Patients" working in close collaborations with Patient Organisations.

Another lingering difficulty to tackle is expenditure on cancer medicines. Lack of adequate access to cancer medicines remains an issue, with high prices often considered as the main contributory factor. It is in response to this alarming scenario that OECl is a working party of the European Fair Pricing Network, an initiative that promotes activities of research and advocacy, which may help secure fairer prices of cancer medicines and enable affordable, population-wide access to cancer drugs all across Europe.

OECl's WG Biobanks and Molecular Pathobiology, a highly proactive Working Group aims to promote and disseminate molecular approaches for tumor stratification, and prognostic criteria.

Finally, it has become more and more clear to us that both the public and private sector need to be involved. This is why our Cancer Outcomes Research Working Group has been deeply involved in designing and promoting the DIGital Institute for Cancer Outcomes REsearch, a European network open to all OECl cancer centres interested in participating.

DIGICORE is the result of the partnership of some 20 stakeholders which came together in a pan-EU research collaboration to study patient cancer outcomes. In a few words, an exciting opportunity designed by several prominent cancer centres, three national networks (UNICANCER, Alleanza Contro il Cancro and the German National Molecular Genomic Consortium), as well as segments of the industry (IQVIA).

We would hereby like to thank the chairs of our WGs, Dominique de Valeriola, Wim van Harten, Giorgio Stanta, Giovanni Apolone and Simon Oberst for their precious contribution to the OECl activities and initiatives.

This year, despite the difficulties linked to the pandemic, the OECl activities have not been reduced and, at least, our budget benefit from the obligation to smartwork which has been also been the case for the A&D site visit that have been realised by a virtual approach.

The reduction on regular costs gave us the opportunity to invest, part of the positive balance by **financing three "one-shot" projects**. After receiving a number of proposals from our WGs, and the A&D Programme, the OECl Board agreed to allocate €40.000 to the proposal put forward by the Cancer Outcome Research WG on **"Patient Reported Outcome and Patient Reported Evidence measures in Real World Data and Real World Evidence studies"**. Another €30.000 will be allocated to the Health Economics WG and their proposal on **"Financial toxicity in breast-, colorectal-, head and neck cancer patients within a multi-country framework"** and finally, €40.000 have been allocated to the A&D

Programme and their proposal to carry out a Research, a Conference, and a Publication on:  
**"What is a comprehensive approach to cancer?"**

For all the briefly listed activities, we have to thank the Board and the Extended Board members and also the OECI Director, Claudio Lombardo and his team at the OECI Liaison Office, for their professionalism, dedication and competence.

I firmly believe OECI **is the Way to Quality** and that together we can reach the ambitious goals we set and that the interests of individuals will not prevail over the expectations of our patients who must always be at the centre of all our efforts.

Once again, I would like to thank the Fondazione IRCCS - Istituto Nazionale dei Tumori for kindly accepting to host and organise the 2021 Edition the OECI Oncology Days.



**Thierry Philip**  
OECI President



**Giovanni Apolone**  
OECI President Elect

OECI thanks the  
**Fondazione IRCCS - Istituto Nazionale dei Tumori**  
 for kindly accepting to organise the 43<sup>rd</sup> Edition  
 of the OECI Oncology Days



**Fondazione IRCCS**  
Istituto Nazionale dei Tumori



**Sistema Socio Sanitario**  
**Regione Lombardia**

**Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano**

[www.istitutotumori.mi.it](http://www.istitutotumori.mi.it)

Referring Number  
ID 11  
Full Member



## Director's foreword

Fondazione IRCCS - Istituto Nazionale dei Tumori has always supported the OECI because we are convinced that collaboration and intensive networking among cancer institutes are essential to face the complex challenge posed by cancer to patients, healthcare stakeholders and society. Together with the other OECI members, we are proud to contribute by delineating and pursuing a common strategy in the battle against cancer and in the fight against inequalities in treatment within Europe.

## Description of the Centre and history

Since its establishment in 1928, INT has always aimed to provide the highest standard of patient care while pursuing preclinical and clinical research and promoting its swift translation into better prevention, diagnosis, therapy, rehabilitation, and survival.

## Main research activities

Current research includes investigation of molecular and cellular determinants and mechanisms of tumor onset, growth and progression, as well as analysis of inherited factors underlying genetic susceptibility to cancer. More therapeutically oriented studies are aimed at developing and selecting new target-specific agents. Identification of growth signals and checkpoint functions driving cell proliferation and survival is essential for the detection and validation of predictors of tumor progression and treatment response, and helps define new targets for drug therapy and novel therapeutic approaches that modulates cellular response by combining chemopreventive and anticancer agents. Antitumor immunity and the regulatory mechanisms interfering with the immune recognition of tumor cells are also being studied. Finally, crucial in designing and conducting prospective clinical studies is the strong and continuous collaboration between the Experimental Oncology and Clinical Departments. Epidemiological and translational research aims to gain knowledge of lifestyle and genetic risk factors for use in cancer prevention. We also look out for inequalities in prevention and treatment so that corrective action can be taken.

In this field, we focus on dietary intervention studies targeting the general population, high-risk subgroups, and cancer patients to minimize the risk of recurrence; the study of inequalities in survival and cure rates of cancer patients as the systematic description of cancer incidence, prevalence, and survival explains survival differences between and within countries, to devise actions that may reduce such inequalities; research on environmental and occupational risk factors, from standard epidemiological designs to the systematic monitoring of occupational risk by linking cancer registry data and occupational history files.

## Core Facilities

Core facilities and equipment for research at INT include 1) a collection of annotated biological specimens with known clinical history; 2) updated databases with clinical information on patients enrolled in clinical studies; 3) laboratories for tissue culture, molecular biology, pathology and biochemistry; 4) a functional genomics facility with Illumina and Agilent platforms, and instrumentation for next-generation and Sanger sequencing; 5) statistical support for planning correlative and integrated translational research studies.

## Education

PhD studentships, postdoctoral research fellowships, graduate student training, medical, nursing, psychology and social service training as well as continuing medical education are in our portfolio of educational opportunities. We provide education and training at a postgraduate level by offering a range of highly specialised Master courses, running the PhD programme of the Open University (about 20 students), and hosting about 30 PhD students from other universities.

## The OECI Board



**President**  
**Thierry Philip**  
Paris, France



**Vice-President and Executive Secretary**  
**Giovanni Apolone**  
Milan, Italy



**Treasurer**  
**Manuel Llombart Fuertes**  
Valencia, Spain



**Elected Member**  
**Christian Brandts**  
Frankfurt, Germany



**Elected Member**  
**József Lövey**  
Budapest, Hungary



**Elected Member**  
**Simon Oberst**  
Cambridge, United Kingdom



**Elected Member**  
**Gunnar Sæter**  
Oslo, Norway



**Elected Member**  
**Marien van der Meer**  
Amsterdam, The Netherlands



**OECI Director**  
**Claudio Lombardo**  
Brussels, Belgium - Genoa, Italy



**OECI Central Office**  
**Guy Storme**  
Brussels, Belgium

## Accreditation and Designation Programme



**Simon Oberst**  
Cambridge, United Kingdom

## Working Groups



**Biobanks and Molecular Pathobiology**  
**Giorgio Stanta**  
Trieste, Italy



**Cancer Outcomes Research**  
**Milena Sant**  
Milan, Italy



**Cancer Economics and Benchmarking**  
**Wim H. van Harten**  
Amsterdam, The Netherlands



**Collaboration for Good Practices with Patients**  
**Dominique de Valeriola**  
Brussels, Belgium


OECI-EEIG Central Office - c/o Fondation Universitaire - 11, Rue d'Egmont  
Phone: +32 2 512 0146, B-1000 Brussels, Belgium

# OECI2021 ONCOLOGY DAYS

## The OECI Network



- ★ OECI Members A&D certified Comprehensive Cancer Centre
- ★ OECI Members A&D certified Cancer Centre
- ★ OECI Members in the A&D process
- Other OECI Members



## The OECI membership

### Austria

- ★ Comprehensive Cancer Center Vienna, Vienna

### Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ AZ Groeninge, Kortrijk
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

### Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

### Colombia

- ★ Instituto Nacional de Cancerología – ESE, Bogotá

### Croatia

- ★ Klinika za tumore Klinički bolnički centar Sestre milosrdnice, Zagreb

### Czech Republic

- ★ Masarykův onkologický ústav, Brno
- ★ Fakultní nemocnice v Motole, Prague
- ★ Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

### Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- ★ Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen

### Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- ★ North Estonia Medical Centre, Tallin

### Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Cancer Centre Tampere University Hospital, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu

### France

- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Centre François Baclesse, Caen
- ★ APHP-CARPEM Institute, Paris
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Association Toulousaine de Oncologie Publique (ATOP), Toulouse

- ★ Gustave Roussy, Villejuif
- ★ Institut de cancérologie Strasbourg Europe ICANS, Strasbourg
- ★ Centre Jean Perrin, Clermont-Ferrand
- ★ Institut du Cancer de Montpellier (ICM), Montpellier
- ★ Institut Godinot, Reims
- ★ Institut de cancérologie des Hospices Civils de Lyon, Lyon
- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris
- ★ Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- ★ Centre Henri Becquerel, Rouen
- ★ Institut Sainte Catherine, Avignon

### Germany

- ★ Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- ★ Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- ★ Charité Comprehensive Cancer Center, Berlin
- ★ Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt

### Hungary

- ★ Országos Onkológiai Intézet, Budapest
- ★ Országos Korányi TBC és Pulmonológiai Intézet, Budapest

### Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont Hospital, Dublin

### Italy

- ★ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ★ Istituto Nazionale Tumori Regina Elena, Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padova
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milano)
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari

- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- ★ Ospedale San Raffaele (OSR), Milano
- ★ Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- ★ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS, Meldola (Forlì-Cesena)
- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- ★ IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- ★ Istituto Dermatologico San Gallicano, Roma

### Jordan

- ★ King Hussein Cancer Center, Amman

### Lithuania

- ★ National Cancer Institute, Vilnius

### Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

### Poland

- ★ Wielkopolskie Centrum Onkologii, Poznań

### Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

### Romania

- ★ The "Prof. Dr. Ion Chiricuta" Institute of Oncology (IOCN), Cluj-Napoca
- ★ SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy, Otopeni

### Russia Federation

- ★ Tatarstan Cancer Center "TCC", Kazan
- ★ N.N. Blokhin Russian Cancer Research Centre, Moscow
- ★ National Medical Research Radiological Centre (NMRR), Moscow

### Serbia

- ★ Oncology Institute of Vojvodina, Sremska Kamenica

### Slovakia

- ★ Biomedicínske centrum Slovenskej akadémie vied, Bratislava

### Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

### Spain

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

### Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Sahlgrenska University Hospital, Göteborg
- ★ Uppsala University Hospital, Uppsala

### Switzerland

- ★ Comprehensive Cancer Center Zürich (CCCZ), Zürich

### Tanzania

- ★ The Aga Khan Hospital, Dar es Salaam, Dar es Salaam

### The Netherlands

- ★ Netherlands Cancer Institute, Amsterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- ★ Erasmus MC Cancer Institute, Rotterdam
- ★ IKNL Integraal Kankercentrum Nederland, Utrecht
- ★ Radboudumc Centrum voor Oncologie, Nijmegen
- ★ Rijnstate, Arnhem

### Turkey

- ★ Anadolu Saglik Merkezi, Kocaeli
- ★ Dokuz Eylul Üniversitesi Onkoloji Enstitüsü, Izmir

### Ukraine

- ★ RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

### United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cambridge Cancer Centre, Cambridge
- ★ King's Health Partners Integrated Cancer Centre, London
- ★ Imperial College Healthcare NHS Trust, London

### Viet Nam

- ★ Bệnh viện K Việt Nam National Cancer Hospital, Hanoi



## Programme

09:00 **Opening Session**

### Welcome from the Hosts

*Giovanni Apolone - OECD President Elect*

*Maria Cristina Messa - Italian Minister of University & Research*

*Giovanni Leonardi - Director General Research - Italian Ministry of Health*

### Introduction

*Thierry Philip - OECD President*

*Walter Ricciardi - Chair European Cancer Mission Board*

09.30 **The role of cancer centres in the European Beating Cancer Plan**

*Stella Kyriakides - European Commissioner DG Health and Food Safety*

**10.00 Rebuilding on the successful experiences of patient involvement**

*For OECD centres, patients are bringing a different and valuable perspective to the quality improvement process in hospitals by expressing their special needs and priorities. A true alliance of patient involvement and quality assessment in cancer centres and networks will be key to rebuild a more resilient and humanistic healthcare system.*

10.00 **Patient Involvement: OECD Centres' Greatest Asset for Quality**

*Dominique de Valeriola*

10.05 **Patient Engagement in the Research Unit: a Current Future**

*Chiara Barbieri*

10.20 **A 360° Look at Oncology by Patients for the Patients**

*Emmanuelle Arfe & Amanda Olivon*

10.35 **Tools for a more Personalized Oncological Care: from Digital Narrative Diaries to a Community Sharing Digital Space**

*Maria Cecilia Cercato*

10.50 **Discussion**

**11.00 Private Webinar Session**

Chair: *Patrick Miqueu*

LINK:

<https://zoom.us/j/93889080848?pwd=SSStDejFJdJVaVFhDdE1Gc2EwbEdYZz09>

ID: 938 8908 0848

PASSWORD: 078166

**11.00 Cancer Economics and Benchmarking WG Session:**  
**12.00 "Pricing, Coverage and Access to Innovative Cancer Drugs"**

*This Session deals with access and pricing of innovative and expensive new cancer medicines. In view of the impressive pipeline, one can doubt the financial sustainability of the system. Sabine Vogler from Vienna/Austria will present her findings in comparing list prices and on equity in the access to drugs when comparing EU countries. Further Amithab Chandra from Harvard/Boston will expand on the issue of sustainability of the (cancer-) healthcare system in view of the drug pipeline. Last Nora Franzen from the NCI will present a review of alternative policy options for drug pricing, views from key opinion leaders in the field as well as first results of gaming experiments in generating evidence under these policy options.*

11.00 **Welcome and Update of the European Fair Pricing Network**

*Wim van Harten*

11.05 **Access to innovative cancer drugs in Europe**

*Sabine Vogler*

11.20 **The drug pipeline and financial sustainability of cancer care provision**

*Amitabh Chandra*

11.35 **Innovative policies to reduce drug pricing (review of options and scenarios)**

*Nora Franzen*

*Valesca Retèl*

11.50 **Discussion**

**12.00 Private Webinar Session**

Chair: *Giorgio Stanta*

LINK:

<https://zoom.us/j/99887901940?pwd=eHBSVnJjRUk2YXV1cnpHbkhWNWFNQT09>

ID: 998 8790 1940

PASSWORD: 493270

## **12.00** Biobanks and Molecular Pathobiology WG **13.00** Session: Molecular diagnosis and clinical research reproducibility: a European Mission

Reproducibility and exchangeability of molecular results in diagnostics and clinical research is one of the main arguments of debate in clinical molecular pathology. Specific European projects and initiatives are therefore needed in order to find a large consensus guaranteeing equal approaches across countries. The OEI Biobanking and Molecular Pathobiology WG interacts with several initiatives looking to define a common language in a wider clinical network. The Pathology Day represents therefore an important dissemination step, and the place where to discuss the best approaches to standardise the diagnostic process and to guarantee the reproducibility of results. All this because we have to guarantee the reproducibility and the exchangeability of molecular analyses among European health institutions. There are already different European projects that address directly this necessity and it is extremely important to let know the results of this project to obtain a diffused spreading and application.

12.00 **Welcome and Introduction**  
*Giorgio Stanta*

12.05 **Heterogeneity of cancer: HERCULES project**  
*Olli Carpen*

12.20 **Standardization of pre-analytical procedures for diagnostics and clinical research: SPIDIA4P project**  
*Uwe Oelmueller*

12.35 **Integrated and standardized NGS workflows for personalized therapy: the INSTAND4P project for the evaluation of NGS commercial items**  
*Speaker tbd*

12.50 **Virtual Molecular Tumour Boards**  
*Gennaro Ciliberto*

13.00 *Break*

## **13.00** Private Webinar Session

**14.00** Chair: *Giorgio Stanta*

LINK:

<https://zoom.us/j/93775249562?pwd=ZWxYZG0zS0xaWIM3UXFaYTZDb3BBdz09>

ID: 937 7524 9562

PASSWORD: 507167

## **14.00** Cancer Quality Session: **18.00** Evaluating Quality Improvement in European Cancer Services

The Sessions will:

- Highlight case studies of centres who have improved structures and processes as a result entering the Programme
- Discuss progress in evaluating cancer networks; benchmarking; and excellent practices
- Examine quality from a patient outcomes perspective
- Focus on the place of quality improvement within the EU Cancer Mission and Europe's Beating Cancer Plan, especially regarding Comprehensive Cancer Infrastructures.

14.00 **Plenary Lecture**  
**Evaluating Quality in Cancer Care and Research in Europe**  
*Simon Oberst*

**1<sup>st</sup> Workshop**  
14.20 **Developments in the OEI Quality Programme**  
*Moderator: Mef Nilbert*

14.20 **Specific developments in the OEI A&D Programme in 2020-2021:**

- Virtual audits
- Network Standards and evaluation
- Excellent practices project

*Wim van Harten*

14.40 **Case Studies from Audited Centres: What Improvements has the OEI process driven?**  
**2 invited presentations (10 minutes each)**

- Dublin (*Paul Browne*)
- Helsinki (*Johanna Mattson*)

15.00 **Benchmarking comprehensiveness – data from OEI's accredited centres**  
*József Lövey*

15.15 **Questions and Discussion**



## 2<sup>nd</sup> Workshop

### 15.25 Measuring Quality outcomes

Moderator: **Dominique de Valeriola**

### 15.25 How Quality of Life assessment can improve quality of care

**Lonneke van De Poll**

### 15.40 Quality related to patient outcomes research

**Giovanni Apolone**

### 16.00 Questions and Discussion

### 16.15 Break

## 3<sup>rd</sup> Workshop

### 16.30 Quality in the context of the aims of the EU Cancer Mission and Europe's Beating Cancer Plan

Moderator: **Peter Nagy**

### 16.30 The Importance of integrating cancer research and clinical care

**Gunnar Saeter**

### 16.45 The Vision of the EU Cancer Mission Board for Comprehensive Cancer Infrastructures

**Christine Chomienne** - Vice-Chair of the EU Cancer Mission

### 17.00 IPAAC Joint Action – to the finish line

**Tit Albreht**

### 17.15 Driving up quality in Cancer Research (including the European Academy of Cancer Sciences Designation of Research Excellence)

**Anton Berns**

### 17.30 OECD's contribution to setting up a Comprehensive Cancer Infrastructure in Member States

**Thierry Philip**

### 17.45 Questions and Discussion

### 18.00 Closing remarks

**Simon Oberst**

## Invited speakers

### Tit Albreht

National Institute of Public Health  
Ljubljana, Slovenia

### Giovanni Apolone

Fondazione IRCCS INT  
Milan, Italy

### Emmanuelle Arfe

IUCT Oncopole  
Toulouse, France

### Anton Berns

European Academy of Cancer Science  
Brussels, Belgium

### Chiara Barbieri

AIBAT, Italy

### Paul Browne

Trinity St. James's Cancer Institute  
Dublin, Ireland

### Olli Carpen

University of Helsinki  
Helsinki, Finland

### Maria Cecilia Cercato

IRCCS Istituto Nazionale Tumori Regina Elena  
Rome, Italy

### Amitabh Chandra

Harvard Business School  
Boston, The USA

### Christine Chomienne (tbc)

Vice President European Cancer Mission

### Gennaro Ciliberto

IRCCS Istituto Nazionale Tumori Regina Elena  
Rome, Italy

### Dominique de Valeriola

Institut Jules Bordet  
Brussels, Belgium

### Nora Franzen

Netherlands Cancer Institute  
Amsterdam, The Netherlands

### Stella Kyriakides

European Commissioner  
DG Health and Food Safety  
Brussels, Belgium

### Giovanni Leonardi

Ministero della Salute  
Rome, Italy

### József Lövey

National Cancer Institute  
Budapest, Hungary

### Johan Lundin

University of Helsinki  
Helsinki, Finland

### Johanna Mattson

Helsinki University Hospital  
Helsinki, Finland

### Maria Cristina Messa

Italian Minister of University & Research

### Peter Nagy

National Cancer Institute  
Budapest, Hungary

### Mef Nilbert

Danish Cancer Society Research Center  
Denmark

### Simon Oberst

Cambridge Cancer Centre  
The UK

### Uwe Oelmueller

Qiagen  
Hilden, Germany

### Amanda Olsson

IUCT Oncopole  
Toulouse, France

### Thierry Philip

Institut Curie  
Paris, France

### Valesca Retèl

Netherlands Cancer Institute  
Amsterdam, The Netherlands

### Walter Ricciardi

Chair European Cancer Mission Board  
Oslo University Hospital  
Oslo, Norway

### Giorgio Stanta

University of Trieste  
Trieste, Italy

### Loonneke van De Poll

Amsterdam, The Netherlands

### Wim van Harten

Rijnstate Hospital  
Arnhem, The Netherlands

### Sabine Vogler

Pharmaco-economics Department, GÖG  
Wien, Austria



#### THE OECD 2021 SCIENTIFIC COMMITTEE

##### **President**

Thierry Philip

##### **Members**

Giovanni Apolone, Christian Brandts, Dominique de Valeriola, Manuel Lombart Fuertes, Claudio Lombardo, József Lövey, Simon Oberst, Milena Sant, Gunnar Sæter, Giorgio Stanta, Wim van Harten, Marien van der Meer

#### THE OECD 2021 ONCOLOGY DAYS SECRETARIATS

GENOA: Daniela Garbarino, Giorgia Pesce,  
Roxana Plesoianu, Patrizia Sommella

MILAN: Costanza Bono, Chiara Casati, Eleonora De Palo

PARIS: Anna Fackeure

UNITED KINGDOM: Kelly O'Reilly

THE NETHERLANDS: Willien Westerhuis, Harriët Blaauwgeers

#### OECD 2021 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo - OECD Director

Phone +32 2 512 01 46

[oeeci@oeeci.eu](mailto:oeeci@oeeci.eu) - [www.oeeci.eu](http://www.oeeci.eu)

#### TECHNICAL SERVICE & BROADCASTING

Sa.Ga. Multimedia s.r.l.

[www.sagamultimedia.it](http://www.sagamultimedia.it)

#### *In collaboration with:*



Fondazione IRCCS  
Istituto Nazionale dei Tumori



Regione  
Lombardia

Sistema Socio Sanitario

The participation is free - registration at:  
<http://www.oeeci.eu/Assembly.aspx>